Meeting
2020 ASCO Virtual Scientific Program
Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons.
Authors
Shan Jiang
Bayer U.S. LLC, Whippany, NJ
Shan Jiang , Emi Terasawa , Viviana Garcia Horton , Rajeev Ayyagari , A. Reginald Waldeck , Susan Halabi , Neal D. Shore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5561)
DOI
10.1200/JCO.2020.38.15_suppl.5561
Abstract #
5561
Poster Bd #
142
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Adverse event profiles of apalutamide, enzalutamide, and darolutamide in SPARTAN, PROSPER, and ARAMIS: How confident are we about which drug is safest?
First Author: Joshua Z. Drago
Poster
2021 Genitourinary Cancers Symposium
Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).
First Author: Tomasz M. Beer
Poster
2021 Genitourinary Cancers Symposium
Retrospective cohort analysis of real-world clinical outcomes in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) treated with novel androgen receptor pathway inhibitors (ARPI).
First Author: Richard Gagnon
Poster
2023 ASCO Annual Meeting
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
First Author: Alicia K. Morgans